Clinical Trial Update: Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 study of lumacaftor in combination with ivacaftor in children aged 6 through 11 with cystic fibrosis homozygous for the F508del-CFTR mutation has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2016-12-05